Talk gets fevered over whether Pfizer, J&J or Lilly might make a run at Cubist

The announcement that the FDA will review a second drug candidate from antibiotic specialist Cubist Pharmaceuticals ($CBST), speculation is ramping up that it is ripe for a takeover. Pfizer ($PFE), which has a competing drug for which Cubist hopes to get FDA approval, is one possible suitor being mentioned. Johnson & Johnson ($JNJ) and Eli Lilly ($LLY) are also mentioned as having the cash and competency to make a run at Cubist. Report | More

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.

AZ licenses COVID-19 vaccine to BioKangtai in China. Pfizer and BioNTech will supply 120 million doses of their shot to Japan. Legend CEO resigned.